Clinical Trial Update: EGFR-ADC (Becotatug Vedotin) Combined With PD-1 Inhibitor (Pucotenlimab) in Neoadjuvant Treatment of Advanced Penile Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of an EGFR-directed antibody-drug conjugate with a PD-1 inhibitor as neoadjuvant therapy for advanced penile…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Penile Cancer

Drugs mentioned

• Becotatug Vedotin
• Pucotenlimab

Snippet

Sponsor: Jiyan Liu | Conditions: Penile Cancer | Phase 2 | Status: NOT_YET_RECRUITING